Skip to main content
SpringerLink
Log in

Adverse Effects of Interferon Treatment

  • Conference paper
Interferons

Abstract

Interferons (IFN) are a complex group of naturally occurring proteins and glycoproteins initially recognized as antiviral agents. Because of their antipro-liferative, differentiation-inducing, and immunomodulatory effects in vitro, they have been increasingly used during the last decade to treat a broad spectrum of human diseases including hematological malignancies, solid tumors, viral infections, and AIDS-related complications. The introduction of recombinant DNA techniques permitted large-scale production of highly purified IFN and strongly stimulated systematic clinical investigations. Most of this work was done with IFN-α (leukocyte interferon). There has been sufficient study of IFN-β (fibroblast interferon) to establish that its spectrum of clinical activities is similar to that of IFN-α. Limited information is available concerning the effects of IFN-γ (immune interferon) which is the most potent immunomodulating agent.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Bocci V (1994) Pharmacology and side-effects of interferons. Antiviral Res 24: 111–119

    Article  PubMed  CAS  Google Scholar 

  2. Merimsky 0, Reider-Groswasser I, Inbar M, Chaitchik S (1990) Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 26: 596–600

    Article  Google Scholar 

  3. Prasad S, Waters B, Hill PB, Portera FA, Riely CA (1992) Psychiatric side effects of interferon α2b in patients treated for hepatitis C. Clin Res 40: 840A

    Google Scholar 

  4. Niiranen A, Laaksonen R, Iivanainen M, Mattson K, Farkkila M, Cantell K (1988) Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatr Scand 78: 622–626

    Article  PubMed  CAS  Google Scholar 

  5. Jones GJ, Itri LM (1986) Safety and tolerance of recombinant interferon alfa-2a (Roferon®-A) in cancer patients. Cancer 57: 1709–1715

    Article  PubMed  CAS  Google Scholar 

  6. Adams F, Quesada JR, Gutterman JU (1984) Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. J Am Med Assoc 252: 938–941

    Article  CAS  Google Scholar 

  7. Janssen HLA, Berk L, Vermeulen M, Schalm SW (1990) Seizures associated with low-dose alpha-interferon. Lancet 336: 1580

    Article  PubMed  CAS  Google Scholar 

  8. Meyers JD, Flournoy N, Sanders JE et al (1987) Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med 107: 809–816

    PubMed  CAS  Google Scholar 

  9. Bauherz G, Soeur M, Lustman F (1990) Oculomotor nerve paralysis induced by alpha II-interferon. Acta Neurol Belg 90: 111–114

    PubMed  CAS  Google Scholar 

  10. Manesis EK, Petrou C, Brouzas D, Hadziyannis S (1994) Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 21: 474–477

    Article  PubMed  CAS  Google Scholar 

  11. Read SJ, Crawford DH, Pender MP (1995) Trigeminal sensory neuropathy induced by interferonα therapy. Aust N Z J Med 25: 54

    PubMed  CAS  Google Scholar 

  12. Gastineau DA, Habermann TM, Hermann RC (1989) Severe neuropathy associated with low-dose recombinant interferon-alpha. Am J Med 87: 116

    Article  PubMed  CAS  Google Scholar 

  13. Cudillo L, Catonetti M, Venditti A, Lentini R, Rosini PM, Caramia M, Masi M, Papa G (1990) Peripheral polyneuropathy during treatment with alpha-2 interferon. Haematologica 75: 485–486

    Google Scholar 

  14. Sherwin SA, Knost JA, Feins S, Abrams PG, Foon KA (1982) A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. J Am Med Assoc 248: 2461–2466

    Article  CAS  Google Scholar 

  15. Meyers CA, Scheibel RA, Forman AD (1991) Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 41: 672–676

    PubMed  CAS  Google Scholar 

  16. Koehler SM, Glass JP (1992) Neurotoxicity of interferon-alpha. Neurology 42: 939

    PubMed  CAS  Google Scholar 

  17. Vesikari T, Nuutila A, Cantell K (1988) Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma. Acta Paediatr Scand 77: 619–622

    Article  PubMed  CAS  Google Scholar 

  18. Spiegel RJ (1986) Intron® A (interferon alfa-2b): clinical overview and future directions. Sem Oncol 13 [Suppl 2]: 89–101

    CAS  Google Scholar 

  19. Bocci V (1988) Central nervous system toxicity of interferons and other cytokines. J Biol Regul Homeost Agents 3: 107–118

    Google Scholar 

  20. Hagberg H, Blomkvist E, Ponten U et al (1990) Does alpha-interferon in conjunction with radio-therapy increase the risk of complication in the central nervous system. Ann Oncol 1: 449–451

    PubMed  CAS  Google Scholar 

  21. Laaksonen R, Niiranen A, Iivanainen M, Mattson K, Holsti L (1988) Dementia-like largely reversible syndrome after cranial irradiation and prolonged interferon treatment. Ann Clin Res 20: 201–203

    PubMed  CAS  Google Scholar 

  22. Renault PF, Hoofnagle JH, Park Y et al (1987) Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 147: 1577–1580

    Article  PubMed  CAS  Google Scholar 

  23. Rohatiner AZS, Balkwill FR, Griffin DB, Malpas JS, Lister TA (1982) A phase I study of human lympho-blastoid interferon administered by continuous infusion. Cancer Chemother Pharmacol 9: 97–102

    Article  PubMed  CAS  Google Scholar 

  24. Jacobs L, O’Malley S, Freeman A, Ekes R (1981) Intrathecal IFN reduces exacerbations of MS. Science 214: 1026

    Article  PubMed  CAS  Google Scholar 

  25. Sapolskky R, Packan DR, Vale WW (1988) Glucocorticoid toxicity in the hippocampus: in vitro demonstration. Brain Res 453: 367–371

    Article  Google Scholar 

  26. Dafny N, Zielinksi M, Reyes-Vazquez C (1983) Alteration of morphine withdrawal to naloxone by interferon. Neuropeptides 3: 453–463

    Article  PubMed  CAS  Google Scholar 

  27. Schattner A (1988) Interferons and autoimmunity. Am J Med Sci 295: 532–544

    Article  PubMed  CAS  Google Scholar 

  28. Sacchi S, Kantarjian H, O’Brien S, Cohen PR, Pierce S, Talpaz M (1995) Immune-mediated and unusual complications during interferon alfa therapy of chronic myelogenous leukemia. J Clin Oncol 13: 2401–2407

    PubMed  CAS  Google Scholar 

  29. Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL (1985) Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1: 1166

    Article  PubMed  CAS  Google Scholar 

  30. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH (1992) Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 102: 2155–2160

    PubMed  CAS  Google Scholar 

  31. Baudin E, Narcellin P, Pouteau M et al (1993) Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol 39: 657–661

    Article  CAS  Google Scholar 

  32. Vial T, Descotes J (1994) Clinical toxicity of the interferons. Drug Saf 10: 115–150

    Article  PubMed  CAS  Google Scholar 

  33. Gisslinger H, Gilly B, Woloszczuk W et al (1992) Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 90: 363–367

    Article  PubMed  CAS  Google Scholar 

  34. Rönnblom LE, Alm GV, Oberg KE (1991) Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115: 178–183

    PubMed  Google Scholar 

  35. Watanabe U, Hasimoto E, Hisamitsu T, Obata H, Hayashi N (1994) The risk factor for development of thyroid disease during interferon-a therapy for chronic hepatitis C.Am J Gastroenterol 89: 399–403

    PubMed  CAS  Google Scholar 

  36. Vallisa D, Cavanna L, Berté R, Merli F, Ghisoni F, Buscarini L (1995) Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. Acta Haematol 93: 31–35

    Article  PubMed  CAS  Google Scholar 

  37. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen S (1991) Induction of systemic lupus erythematodes by interferon gamma in a patient with rheumatoid arthritis. J Rheumatol 18: 1621–1622

    PubMed  CAS  Google Scholar 

  38. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M (1991) Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68: 1536–1537

    Article  PubMed  CAS  Google Scholar 

  39. Wandl UB, Nagel-Hiemke M, May D et al (1992) Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 65: 70–74

    Article  PubMed  CAS  Google Scholar 

  40. Rönnblom LE, Alm GV, Öberg KE (1990) Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 227: 207–210

    Google Scholar 

  41. Hess E (1988) Drug-related lupus. N Engl J Med 318: 1460–1462

    Article  PubMed  CAS  Google Scholar 

  42. Chazerain P, Meyer 0, Kahn MF (1992) Rheumatoid arthritis-like disease after alpha-interferon therapy. Ann Intern Med 116: 427

    PubMed  CAS  Google Scholar 

  43. Cleveland MG, Malory SB (1993) Incomplete Reiter’s syndrome induced by systemic interferon a treatment. J Am Acad Dermatol 129: 788–789

    Article  Google Scholar 

  44. Matsuya M, Abe T, Tosaka M et al (1994) The first case of polymyositis associated with interferon therapy. Intern Med 33: 806–808

    Article  PubMed  CAS  Google Scholar 

  45. Greenfield SM, Harvey RS, Thrompson RP (1994) Rhabdomyolysis after treatment with interferon alfa. Br Med J 309: 512

    CAS  Google Scholar 

  46. Becker JC, Winkler B, Klingert S, Bröcker EB (1994) Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 73: 1621–1624

    Article  PubMed  CAS  Google Scholar 

  47. Matsuda J, Saitoh N, Gotoh M et al (1995) High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-a. Am J Gastroenterol 90: 1138–1141

    PubMed  CAS  Google Scholar 

  48. Bick RL, Baker WF (1984) Antiphospholipid and thrombosis syndromes. Semin Thromb Hemost 20: 3–15

    Article  Google Scholar 

  49. Fabris P, Betterle C, Floreani A et al (1992) Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 340: 548

    Article  PubMed  CAS  Google Scholar 

  50. Guerci AP, Guerci B, Levy-Marchal C et al (1994) Onset of insulin-dependent diabetes mellitus after interferon-alfa therapy for hairy cell leukaemia. Lancet 343: 1167–1168

    Article  PubMed  CAS  Google Scholar 

  51. Funk J, Langeland T, Schrumpf E, Hanssen LE (1991) Psoriasis induced by interferonα. Br J Dermatol 125: 463–465

    Article  PubMed  CAS  Google Scholar 

  52. Parodi A, Semino M, Gallo R, Rebora A (1993) Bullous eruption with circulating pemphigus-like antibodies following interferon-alpha therapy. Dermatology 186: 155–157

    Article  PubMed  CAS  Google Scholar 

  53. Steis RG, Van der Molen LA, Lawrence J et al (1990) Erythrocytosis in hairy cell leukaemia following therapy with interferonα. Br J Haematol 75: 133–135

    Article  PubMed  CAS  Google Scholar 

  54. Akard LP, Hoffman R, Elias L, Saiers JH (1986) Alpha-interferon and immune hemolytic anemia. Ann Intern Med 105: 306

    PubMed  CAS  Google Scholar 

  55. Braathen LR, Stavern P (1989) Autoimmune haemolytic anaemia associated with interferon alfa- 2a in patient with mycosis fungoides. Br Med J 298: 1713

    Article  CAS  Google Scholar 

  56. Abdi EA, Brien W, Venner PM (1986) Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol 36: 515–519

    Article  PubMed  CAS  Google Scholar 

  57. Shrestha R, McKinley C, Bilir BM, Everson GT (1995) Possible idiopathic thrombocytopenic purpura associated with natural α interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 90: 1146–1147

    PubMed  CAS  Google Scholar 

  58. Matthey F, Ardeman S, Jones L, Newland AC (1990) Bleeding in immune thrombocytopenic purpura after alpha-interferon. Lancet 335: 471–472

    Article  PubMed  CAS  Google Scholar 

  59. Benjamin S, Bain BJ, Dodsworth H (1991) Severe bleeding associated with worsening thrombocytopenia following α interferon therapy for autoimmune thrombocytopenic purpura. Clin Lab Haematol 13: 315–317

    Article  PubMed  CAS  Google Scholar 

  60. Kurschel E, Metz-Kurschel U, Niederle N, Aulbert E (1991) Investigations of the subclinical and clinical nephrotoxicity of interferon α2B in patients with myeloproliferative syndromes. Ren Fail 13: 87–93

    Article  PubMed  CAS  Google Scholar 

  61. Sriskandan K, Tee DEH, Pettingale KW (1985) Nephrotic syndrome during treatment with interferon. Br Med J 290: 1590–1591

    Article  CAS  Google Scholar 

  62. Averbuch SD, Austin HA, Sherwin SA, Antonovych T, Bunn PA, Longo DL (1984) Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N Engl J Med 310: 32–35

    Article  PubMed  CAS  Google Scholar 

  63. Selby P, Kohn J, Raymond J, Judson I, McElwain T (1985) Nephrotic syndrome during treatment with interferon. Br Med J 290: 1180

    Article  CAS  Google Scholar 

  64. Herrman, Gabriel F (1987) Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-II interferon. N Engl J Med 316: 112–113

    Article  PubMed  CAS  Google Scholar 

  65. Ault BH, Stapleton FB, Gaber L, Martin A, Roy S, Murphy SB (1988) Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 319: 1397–1400

    Article  PubMed  CAS  Google Scholar 

  66. Lederer E, Truong L (1992) Unusual glomerular lesion in a patient receiving long-term interferon alpha. Am J Kidney Dis 20: 516–518

    PubMed  CAS  Google Scholar 

  67. Nair S, Ernstoff MS, Bahnson RR et al (1992) Interferon-induced reversible acute renal failure with nephrotic syndrome. Urology 39: 169–172

    Article  PubMed  CAS  Google Scholar 

  68. Noel C, Vrtovsnik F, Facon T et al (1992) Acute and definitive renal failure in progressive multiple myeloma treated with recombinant interferon alpha-2a: report on two patients. Am J Hematol 41: 298–299

    Article  PubMed  CAS  Google Scholar 

  69. Sawamura M, Matsushima T, Tamura J, Murakami H, Tsuchiya J (1992) Renal toxicity in long-term α-interferon treatment in a patient with myeloma. Am J Hematol 141: 146

    Article  Google Scholar 

  70. Ayub A, Zafar M, Al-Harbi A, Ellis M, Qunubi W (1993) Acute renal failure with a-interferon therapy: a case report. Med Sci Res 21: 123–124

    Google Scholar 

  71. Stratta P, Canavese C, Dogliani M et al (1993) Hemolytic-uremic syndrome during recombinant α interferon treatment for hairy cell leukemia. Ren Fail 15: 559–561

    Article  PubMed  CAS  Google Scholar 

  72. Harvey M, Rosenfeld D, Davies D, Hall BM (1994) Recombinant interferon alpha and hemolytic uremic syndrome: cause or coincidence. Am J Hematol 46: 152–153

    Article  PubMed  CAS  Google Scholar 

  73. Schlaifer D, Dumazer P, Spenatto N et al (1994) Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon α. Am J Haematol 47: 254–255

    Article  CAS  Google Scholar 

  74. Durand JM, Retornaz F, Cretel E, Kaplanski G, Soubeyrand J (1995) Crescentic glomerulonephritis during treatment with interferonα2b. Am J Hematol 48: 140–141

    PubMed  CAS  Google Scholar 

  75. Jadoul M, Piessevaux H, Ferrant A, Cosyns JP, Van Ypersele de Strihou C (1995) Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferonα2b. Nephrol Dial Transplant 10: 111–113

    PubMed  CAS  Google Scholar 

  76. Rettmar K, Kienast J, Van de Loo J (1995) Minimal change glomerulonephritis with reversible proteinuria during interferon 2a therapy for chronic myeloid leukemia. Am J Hematol 49: 355–356

    Article  PubMed  CAS  Google Scholar 

  77. Aul C, Germing U, Gattermann N, Südhoff T, Heyll A (1996) Recurrent reversible nephrotic syndrome during therapy with recombinant interferon alfa.Am J Hematol (in press)

    Google Scholar 

  78. Wilson CB (1991) The renal response to immunologic injury. In: Brenner BM, Rector FC (eds) The kidney, 4th edn. Saunders, Philadelphia, pp 1062–1181

    Google Scholar 

  79. Gresser I, Maury C, Tovey M, Morel-Maroger L, Pontillon F (1976) Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 263: 420–422

    Article  PubMed  CAS  Google Scholar 

  80. Ronco P, Woodrow D, Riviere Y et al (1980) Further studies on the inhibition of lymphocytic choriomeningitis-induced glomerulonephritis by anti-interferon globulin. Lab Invest 43: 37–46

    PubMed  CAS  Google Scholar 

  81. Kramer P, Ten Kate FWJ, Bijnen AB (1984) Recombinant leukocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1: 989–990

    Article  PubMed  CAS  Google Scholar 

  82. Sonnenblick M, Rosin A (1991) Cardiotoxicity of interferon. A review of 44 cases. Chest 99: 557–561

    Article  PubMed  CAS  Google Scholar 

  83. Deyton LR, Walker RE, Kovacs JA et al (1989) Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi’s sarcoma. N Engl J Med 321: 1246–1249

    Article  PubMed  CAS  Google Scholar 

  84. Martino S, Ratanatharathorn V, Karanes C, Samal BA, Sohn YH, Rudnick SA (1987) Reversible arrhythmias observed in patients treated with recombinant alpha-2 interferon. J Cancer Res Clin Oncol 113: 376–378

    Article  PubMed  CAS  Google Scholar 

  85. Schechter D, Nagler A, Ackerstein A et al (1992) Recombinant interleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation. A case report of cardiovascular toxicity with serial echocardiographic evaluation. Cardiology 80: 168–171

    Article  PubMed  CAS  Google Scholar 

  86. Sarna G, Figlin R, Callaghan M (1983) Alpha (human leukocyte) interferon as treatment for non-small cell carcinoma of the lung: a phase II trial. J Biol Response Med 2: 343–347

    CAS  Google Scholar 

  87. Dickson D (1982) Death halts interferon trials in France. Science 218: 772

    Article  PubMed  CAS  Google Scholar 

  88. Cohen MC, Huberman MS, Nesto RW (1988) Recombinant alpha2 interferon-related cardiomyopathy. Am J Med 85: 549–551

    Article  PubMed  CAS  Google Scholar 

  89. Simone G, Iaffaioli VR, La Mura G et al (1988) Reversible heart failure in a non-Hodgkin lymphoma patient being treated with alpha-interferon. Curr Therap Res 44: 78–85

    Google Scholar 

  90. Sonnenblick M, Rosenmann D, Rosin A (1990) Reversible cardiomyopathy induced by interferon. Br Med J 300: 1174–1175

    Article  CAS  Google Scholar 

  91. Guillot P, Barbuat C, Richard B, Jourdan J (1993) Myocardiopathie réversible induite parl—interféron. Therapie 48: 65–66

    CAS  Google Scholar 

  92. Zimmerman S, Adkins D, Graham M, Petruska P, Bowers C, Vrahnos D, Spitzer G (1994) Irreversible severe congestive cardiomyopathy occurring in association with interferon alpha therapy. Cancer Biother 9: 291–299

    Article  PubMed  CAS  Google Scholar 

  93. Zbinden G (1990) Effects of recombinant human alpha-interferon in a rodent cardiotoxicity model. Toxicol Lett 50: 25–35

    Article  PubMed  CAS  Google Scholar 

  94. Massaro E, Borden E, Hawkins M, Wiebe D, Shrago E (1986) Effects of recombinant interferonα2treatment upon lipid concentrations and lipoprotein composition. J Interferon Res 6: 655–662

    Article  PubMed  CAS  Google Scholar 

  95. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU (1986) Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 4: 234–243

    PubMed  CAS  Google Scholar 

  96. Millier H, Hiemke C, Hammes E, Hess G (1992) Subacute effects of interferon-a2 on adrenocorticotropic hormone, Cortisol, growth hormone and prolactin in humans. Psychoneuroendocrinology 17: 459–465

    Article  Google Scholar 

  97. Sakane N, Yoshida T, Yoshioka K, Umekawa T, Kondo M, Shimatsu A (1995) Reversible hypopituitarism after interferon-alfa therapy. Lancet 345: 1305

    Article  PubMed  CAS  Google Scholar 

  98. Janssen HL, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, Hadziyannis S (1993) Fatal hepatic decompensation associated with interferon alfa. Br Med J 306: 107–108

    Article  CAS  Google Scholar 

  99. Motoo Y, Watanabe H, Okai T, Sawabu N (1994) Interferon-induced pancreatic injury. J Clin Gastroenterol 19: 268–269

    Article  PubMed  CAS  Google Scholar 

  100. Abdi EA, Nguyen GK, Ludwig RN, Dickout WJ (1987) Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer 59: 896–900

    Article  PubMed  CAS  Google Scholar 

  101. Moriya K, Yasuda K, Koike K et al (1994) Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C. J Gastroenterol 29: 514–517

    Article  PubMed  CAS  Google Scholar 

  102. Ogata K, Koga T, Yagawa K (1994) Interferon-induced bronchiolitis obliterans organizing pneumonia. Chest 106: 612–613

    Article  PubMed  CAS  Google Scholar 

  103. Browett PJ, Nelson J, Tiwari S, Van de Water NS, May S, Palmer SJ (1994) Graft-versus-host disease following interferon therapy for relapsed chronic myeloid leukaemia post allogeneic bone marrow transplantation. Bone Marrow Transplant 14: 614–614

    Google Scholar 

  104. Guyer DR, Tiedeman J, Yannuzzi LA et al (1993) Interferon-associated retinopathy. Arch Ophthalmol 111: 350–356

    PubMed  CAS  Google Scholar 

  105. Kanda Y, Shigeno K, Kinoshita N, Nakao K, Yano M, Matsuo H (1994) Sudden hearing loss associated with interferon. Lancet 343: 1134–1135

    Article  PubMed  CAS  Google Scholar 

  106. Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman JW (1994) Increased incidence of second neoplasms in patients treated with interferon 012b for hairy cell leukemia: a clinicopathologic assessment. Blood 83: 2931–2938

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. Aul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Gattermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U. Germing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Heyll
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany

    Carlo Aul  & Wolfgang Schneider  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Aul, C., Gattermann, N., Germing, U., Heyll, A. (1997). Adverse Effects of Interferon Treatment. In: Aul, C., Schneider, W. (eds) Interferons. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60411-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60411-9_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-61051-9

  • Online ISBN: 978-3-642-60411-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation